The consistent improvements in GETE, lung function, and PROs, and reductions in asthma exacerbations, OCS use, and HCRU with add-on omalizumab in real-life confirm and complement the efficacy data of RCTs.
No takes yet. Share an insight, caveat, or question.
Bousquet et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: